Discover 1,912 paid clinical trials in Fort Worth, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Fort Worth offers a range of medical research opportunities, focusing on conditions such as cancer, cardiovascular disease, PTSD, and COVID-19. Healthy volunteers looking for paid opportunities, as well as those with specific health concerns, can participate in studies at the city’s leading healthcare facilities, gaining access to new and innovative treatments while contributing to advancements in medical research.
Filter
2
Filter results
Results: 1,912
Predicting BCG Response
for
Bladder Cancer
Location: Dallas TX, Los Angeles CA, San Francisco CA
Sponsor: Cedars-Sinai Medical Center
Sex: All
Age: 18 - 70+
Code: NCT04564781
Recruiting
Digoxin Medulloblastoma Study
for
Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Location: Dallas TX, Little Rock AR, St Louis MO, Birmingham AL,
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All
Age: 1 - 30
Code: NCT06701812
Phase2, Recruiting
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
for
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer,
Location: Dallas TX, Nashville TN
Sponsor: Vanderbilt-Ingram Cancer Center
Sex: All
Age: 18+
Code: NCT05919108
Phase2, Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
for
Hematuria - Cause Not Known
Location: Dallas TX, Mobile AL, Homewood AL, Nashville TN,
Sponsor: Pacific Edge Limited
Sex: All
Age: 18 - 70+
Code: NCT06394869
Recruiting
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
Location: Dallas TX, San Antonio TX, Houston TX, Saint Louis MO,
Sponsor: TransMedics
Sex: All
Age: 0+
Code: NCT05940857
Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Dallas TX, San Antonio TX, Houston TX, Little Rock AR,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06297226
Phase2, Recruiting
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
for
Relapsed or Refractory Acute Myeloid Leukemia (AML),
Location: Dallas TX, Houston TX, Charleston SC
Sponsor: Institut de Recherches Internationales Servier
Sex: All
Age: 18+
Code: NCT02074839
Phase1, Recruiting
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
for
Prostate Cancer, Prostate Adenocarcinoma
Location: Dallas TX, Chicago IL, Portland OR
Sponsor: University of Chicago
Sex: Male
Age: 18+
Code: NCT05726292
Phase2, Recruiting
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
for
Liver Fibroses, Cirrhosis
Location: Dallas TX, Boston MA
Sponsor: Raymond Chung
Sex: All
Age: 18+
Code: NCT05028829
Phase2, Recruiting
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
for
FSHD
Location: Dallas TX, Austin TX, Kansas City KS, Aurora CO,
Sponsor: University of Kansas Medical Center
Sex: All
Age: 0+
Code: NCT04635891
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
for
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma,
Location: Dallas TX, Houston TX, Columbus OH, Canton OH,
Sponsor: OncoNano Medicine, Inc.
Sex: All
Age: 18+
Code: NCT06022029
Phase1, Recruiting
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
for
Heart Failure With Preserved Ejection Fraction (HFpEF)
Location: Dallas TX
Sponsor: Secretome Therapeutics
Sex: All
Age: 18+
Code: NCT06560762
Phase1, Recruiting
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments